Claris Lifesciences surges on the bourses

28 Jul 2016 Evaluate

Claris Lifesciences is currently trading at Rs. 256.25, up by 10.80 points or 4.40% from its previous closing of Rs. 245.45 on the BSE.

The scrip opened at Rs. 247.50 and has touched a high and low of Rs. 258.95 and Rs. 247.50 respectively. So far 349589 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 270.00 on 26-Jul-2016 and a 52 week low of Rs. 126.10 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 270.00 and Rs. 210.00 respectively. The current market cap of the company is Rs. 1392.02 crore.

The promoters holding in the company stood at 60.99%, while Institutions and Non-Institutions held 21.64% and 17.36% respectively. 

Claris Lifesciences along with its subsidiaries (Claris) has received the Abbreviated New Drug Application (ANDA) approval for Bupivacaine Hydrochloride in 8.25% Dextrose Injection USP, 7.5 mg/mL, Single-dose Ampules with 2ml fill volumes, in the United States of America (US).

With this approval, Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be a little above $300 million. The company expects more product approvals during the year, which will allow it to continue its growth in the US market.

Bupivacaine Hydroxhloride in Dextorse Injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.

 

Peers
Company Name CMP
Redington 271.15
Adani Enterprises 2231.85
Amrapali Industries 14.81
Rashi Peripheral 357.00
PDS 366.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×